Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ViiV Healthcare
Pharma
GSK to triple long-acting Apretude supply to boost global access
The long-acting HIV PrEP maker pledged at least 2 million doses for low-and middle-income countries in 2025 and 2026.
Zoey Becker
Oct 7, 2024 10:56am
WHO flags increasing resistance to GSK's Tivicay in 4 countries
Mar 6, 2024 2:02pm
GSK's long-acting HIV med beats daily pills in some patients
Feb 21, 2024 2:00am
Colombia to seek compulsory license on ViiV's dolutegravir
Oct 4, 2023 3:00pm
GSK sees £7B in HIV sales by 2026, updates next-gen timelines
Sep 28, 2023 9:00am
MSF calls out GSK's ViiV for nondisclosure clauses in contract
Aug 17, 2023 2:54pm
